Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197869
Title: | Inhaled corticosteroids for the treatment of COVID-19 |
Author: | Bafadhel, Mona Faner, Rosa Taillé, Camille Russell, Richard E. K. Welte, Tobias Barnes, Peter J. Agustí García-Navarro, Àlvar |
Keywords: | Asma Corticosteroides COVID-19 SARS-CoV-2 Asthma Adrenocortical hormones COVID-19 SARS-CoV-2 |
Issue Date: | 2022 |
Abstract: | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms |
Note: | Reproducció del document publicat a: https://doi.org/10.1183/16000617.0099-2022 |
It is part of: | European Respiratory Review, 2022, vol. 31, p. 220099 |
URI: | http://hdl.handle.net/2445/197869 |
Related resource: | https://doi.org/10.1183/16000617.0099-2022 |
ISSN: | 0905-9180 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
727736.pdf | 588.79 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License